BioAge Labs Inc (BIOA)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

BioAge Labs Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

BioAge Labs is a clinical-stage biopharmaceutical company developing drug candidates for metabolic diseases through its technology platform analyzing human aging biology. Its lead candidate BGE-102 is an oral small-molecule NLRP3 inhibitor being evaluated in trials for cardiometabolic disease and diabetic macular edema. The company also develops apelin receptor agonists for obesity treatment.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the BioAge Labs Inc stock.

Our verdict on BIOA

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover one fiscal year and projecting growth needs four in a row.

ETFs with the most weight in BIOA

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than BIOA in Drug Manufacturers - Specialty & Generic

33 more in this industry show a wider margin of safety.

Is BIOA undervalued or overvalued?

We do not publish a verdict on BIOA yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover one fiscal year so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of BIOA?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover one fiscal year so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.